To evaluate the efficacy of sorafenib monotherapy, we enrolled 188 patients with
hepatocellular carcinoma (HCC) who had undergone sorafenib monotherapy during a 3 …

Background & Aims No established therapies for patients with hepatocellular carcinoma
(HCC) and progression on first-line sorafenib treatment currently exist. This phase I/II trial …

Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma Page 1
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma Ghassan K …

Purpose: In REFLECT, lenvatinib demonstrated an effect on overall survival (OS) by
confirmation of noninferiority to sorafenib in unresectable hepatocellular carcinoma. This …

Background/purpose Lenvatinib (an inhibitor of vascular endothelial growth factor (GF)
receptors 1–3, fibroblast GF receptors 1–4, platelet-derived GF receptor α, rearranged …

Aim The optimal choice between sorafenib (SOR) or lenvatinib (LEN) as the first‐line
treatment for unresectable hepatocellular carcinoma (u‐HCC) remains debatable. Using …

TPS4153 Background: Lenvatinib (L, E7080) is an oral multi-targeted tyrosine kinase
inhibitor of VEGFR1-3, FGFR1-4, PDGFRβ, RET and KIT. Given the role of angiogenesis in …

ABSTRACT Introduction: Since 2007 Sorafenib has represented the only approved drug for
first-line treatment of advanced hepatocellular carcinoma (HCC). Lenvatinib, an orally active …

Introduction: Sorafenib is the only systemic drug approved for the treatment of advanced
hepatocellular carcinoma (HCC). Within recent years, several investigational agents mainly …

Background Lenvatinib has been approved for use in the systemic treatment for
unresectable hepatocellular carcinoma (HCC). This study aimed to investigate the efficacy …